SNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sanofi SA (SNY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown positive financial performance in Q1 and strong demand for its flagship product Dupixent, the technical indicators and recent analyst ratings suggest a neutral to cautious outlook. The lack of significant trading signals and mixed sentiment from analysts further support a hold recommendation.
The MACD is negative and expanding, RSI is neutral at 53.545, and moving averages are converging, indicating no clear trend. Key support and resistance levels are at 46.407 and 48.347, respectively, suggesting limited upside potential in the near term.
Sanofi's Q1 earnings exceeded expectations with €1.88 EPS and €10.51 billion in revenue, driven by a 30.8% increase in Dupixent sales. Dupixent's approval for pediatric indications in the U.S. expands its market potential.
Technical indicators show no clear bullish trend.
Sanofi reported strong Q1 2026 results with €10.51 billion in revenue, a 6.3% YoY increase, and €1.88 EPS, exceeding expectations. Dupixent sales grew significantly, contributing to overall performance.
Analyst sentiment is mixed, with recent downgrades from BNP Paribas and BofA citing limited pipeline catalysts and leadership uncertainty. Price targets range from EUR 80 to EUR 110, with most analysts maintaining Neutral ratings.
